Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyasu Yamamoto

Showing results (31-40 of 170) with videos related to

Pageof 17
Sort By:
BMJ Open|June 17, 2019
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studiesTadao Akizawa, Megumi Taguchi, Yoshimi Matsuda, et al.
American Journal of Nephrology|September 27, 2021
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 StudyHiroyasu Yamamoto, Kiyoshi Nobori, Yoshimi Matsuda, et al.
American Journal of Nephrology|September 27, 2021
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 TrialHiroyasu Yamamoto, Kiyoshi Nobori, Yoshimi Matsuda, et al.
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|September 24, 2004
[Hyperammoniemia due to portal-systemic shunt developed after initiation of hemodialysis in a chronic renal failure patient]Makoto Kondo, Hiroyasu Yamamoto, Masato Ikeda, et al.
American Journal of Nephrology|November 2, 2021
Letter in Response to "HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety"Hiroyasu Yamamoto, Kiyoshi Nobori, Yoshimi Matsuda, et al.
Nephron|March 17, 2023
Challenges Posed by the Banff Classification: Diagnosis and Treatment of Chronic Active T-Cell-Mediated RejectionIzumi Yamamoto, Mayuko Kawabe, Ayaka Hayashi, et al.
Brain Injury|April 12, 2025
Successful cognitive rehabilitation for acute right frontal aslant tract injury with impaired working memory and inattention using diffusion tensor tractographyMasaharu Sawaki, Kazuya Motomura, Hiroyasu Yamamoto, et al.
Kidney International|May 1, 2010
Should the targeted value of the phosphate be reviewed in the normal range from the viewpoint of vascular calcification?Keitaro Yokoyama, Hiraku Yoshida, Yukio Maruyama, et al.
Calcified Tissue International|April 19, 2011
Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patientsJun Mitome, Hiroyasu Yamamoto, Mitsuru Saito, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|July 26, 2021
Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 studyTadao Akizawa, Kiyoshi Nobori, Yoshimi Matsuda, et al.
Pageof 17

Showing results (31-40 of 170) with videos related to

Sort By:
Pageof 17
BMJ Open|June 17, 2019
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studiesTadao Akizawa, Megumi Taguchi, Yoshimi Matsuda, et al.
American Journal of Nephrology|September 27, 2021
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 StudyHiroyasu Yamamoto, Kiyoshi Nobori, Yoshimi Matsuda, et al.
American Journal of Nephrology|September 27, 2021
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 TrialHiroyasu Yamamoto, Kiyoshi Nobori, Yoshimi Matsuda, et al.
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|September 24, 2004
[Hyperammoniemia due to portal-systemic shunt developed after initiation of hemodialysis in a chronic renal failure patient]Makoto Kondo, Hiroyasu Yamamoto, Masato Ikeda, et al.
American Journal of Nephrology|November 2, 2021
Letter in Response to "HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety"Hiroyasu Yamamoto, Kiyoshi Nobori, Yoshimi Matsuda, et al.
Nephron|March 17, 2023
Challenges Posed by the Banff Classification: Diagnosis and Treatment of Chronic Active T-Cell-Mediated RejectionIzumi Yamamoto, Mayuko Kawabe, Ayaka Hayashi, et al.
Brain Injury|April 12, 2025
Successful cognitive rehabilitation for acute right frontal aslant tract injury with impaired working memory and inattention using diffusion tensor tractographyMasaharu Sawaki, Kazuya Motomura, Hiroyasu Yamamoto, et al.
Kidney International|May 1, 2010
Should the targeted value of the phosphate be reviewed in the normal range from the viewpoint of vascular calcification?Keitaro Yokoyama, Hiraku Yoshida, Yukio Maruyama, et al.
Calcified Tissue International|April 19, 2011
Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patientsJun Mitome, Hiroyasu Yamamoto, Mitsuru Saito, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|July 26, 2021
Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 studyTadao Akizawa, Kiyoshi Nobori, Yoshimi Matsuda, et al.
Pageof 17